Concepedia

Donghwa Kim

DK

30

Publications

1.5K

Citations

22

H-Index

2000

Active since

Affiliations

Seoul National University(Current)

Moffitt Cancer Center

Shenyang Pharmaceutical University

Molecular Oncology (United States)

University of South Florida

Donghwa Kim is an author at Seoul National University specializing in medicine, cell biology, and pharmacology.

ORCID

Top concepts

Publications per year

2000–2021

30

Publications

30

Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells

Sangkil Nam, Donghwa Kim, Jin Cheng et al. · Cancer Research · 2005 · 371 citations · Full text

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

Donghwa Kim, Duc‐Hiep Bach, Yanhua Fan et al. · Cell Death and Disease · 2019 · 98 citations · Full text

PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53

Gaofeng Cui, Sungman Park, Aimee I. Badeaux et al. · Nature Structural & Molecular Biology · 2012 · 97 citations · Full text

, , +6

Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells

Duc‐Hiep Bach, Donghwa Kim, Song Yi Bae et al. · Molecular Therapy — Nucleic Acids · 2018 · 83 citations · Full text

Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.

Donghwa Kim, George Z. Cheng, Craig W. Lindsley et al. · PubMed · 2005 · 80 citations

, , +16

Rows per page

1–5 of 30